Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus Species

Frank Christopher Odds, R. Andrade, J. Bille, E. Canton, M. Cuenca-Estrella, Amanda Denise Davidson, C. Durussel, D. Ellis, E. Foraker, A. W. Fothergill, M. A. Ghannoum, R. A. Giacobbe, M. Gobernado, R. Handke, M. Motyl

    Research output: Contribution to journalArticle

    113 Citations (Scopus)

    Abstract

    Seventeen laboratories participated in a study of interlaboratory reproducibility with caspofungin microdilution susceptibility testing against panels comprising 30 isolates of Candida spp. and 20 isolates of Aspergillus spp. The laboratories used materials supplied from a single source to determine the influence of growth medium (RPMI 1640 with or without glucose additions and antibiotic medium 3 [AM3]), the same incubation times (24 h and 48 h), and the same end point definition (partial or complete inhibition of growth) for the MIC of caspofungin. All tests were run in duplicate, and end points were determined both spectrophotometrically and visually. The results from almost all of the laboratories for quality control and reference Candida and Aspergillus isolates tested with fluconazole and itraconazole matched the NCCLS published values. However, considerable interlaboratory variability was seen in the results of the caspofungin tests. For Candida spp. the most consistent MIC data were generated with visual "prominent growth reduction" (MIC2) end points measured at 24 h in RPMI 1640, where 73.3% of results for the 30 isolates tested fell within a mode one dilution range across all 17 laboratories. MIC2 at 24 h in RPMI 1640 or AM3 also gave the best interlaboratory separation of Candida isolates of known high and low susceptibility to caspofungin. Reproducibility of MIC data was problematic for caspofungin tests with Aspergillus spp. under all conditions, but the minimal effective concentration end point, defined as the lowest caspofungin concentration yielding conspicuously aberrant hyphal growth, gave excellent reproducibility for data from 14 of the 17 participating laboratories.

    Original languageEnglish
    Pages (from-to)3475-3482
    Number of pages7
    JournalJournal of Clinical Microbiology
    Volume42
    Issue number8
    DOIs
    Publication statusPublished - 2004

    Keywords

    • IN-VITRO ACTIVITY
    • MK-0991 L-743,872
    • ANTIFUNGAL AGENTS
    • AMPHOTERICIN-B
    • ECHINOCANDIN
    • LY303366
    • RESISTANT
    • FUSARIUM
    • FUNGI
    • ETEST

    Cite this

    Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus Species. / Odds, Frank Christopher; Andrade, R.; Bille, J.; Canton, E.; Cuenca-Estrella, M.; Davidson, Amanda Denise; Durussel, C.; Ellis, D.; Foraker, E.; Fothergill, A. W.; Ghannoum, M. A.; Giacobbe, R. A.; Gobernado, M.; Handke, R.; Motyl, M.

    In: Journal of Clinical Microbiology, Vol. 42, No. 8, 2004, p. 3475-3482.

    Research output: Contribution to journalArticle

    Odds, FC, Andrade, R, Bille, J, Canton, E, Cuenca-Estrella, M, Davidson, AD, Durussel, C, Ellis, D, Foraker, E, Fothergill, AW, Ghannoum, MA, Giacobbe, RA, Gobernado, M, Handke, R & Motyl, M 2004, 'Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus Species' Journal of Clinical Microbiology, vol. 42, no. 8, pp. 3475-3482. https://doi.org/10.1128/JCM.42.8.3475-3482.2004
    Odds, Frank Christopher ; Andrade, R. ; Bille, J. ; Canton, E. ; Cuenca-Estrella, M. ; Davidson, Amanda Denise ; Durussel, C. ; Ellis, D. ; Foraker, E. ; Fothergill, A. W. ; Ghannoum, M. A. ; Giacobbe, R. A. ; Gobernado, M. ; Handke, R. ; Motyl, M. / Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus Species. In: Journal of Clinical Microbiology. 2004 ; Vol. 42, No. 8. pp. 3475-3482.
    @article{7a9c39bce9974018bdef019dd5cd1a4e,
    title = "Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus Species",
    abstract = "Seventeen laboratories participated in a study of interlaboratory reproducibility with caspofungin microdilution susceptibility testing against panels comprising 30 isolates of Candida spp. and 20 isolates of Aspergillus spp. The laboratories used materials supplied from a single source to determine the influence of growth medium (RPMI 1640 with or without glucose additions and antibiotic medium 3 [AM3]), the same incubation times (24 h and 48 h), and the same end point definition (partial or complete inhibition of growth) for the MIC of caspofungin. All tests were run in duplicate, and end points were determined both spectrophotometrically and visually. The results from almost all of the laboratories for quality control and reference Candida and Aspergillus isolates tested with fluconazole and itraconazole matched the NCCLS published values. However, considerable interlaboratory variability was seen in the results of the caspofungin tests. For Candida spp. the most consistent MIC data were generated with visual {"}prominent growth reduction{"} (MIC2) end points measured at 24 h in RPMI 1640, where 73.3{\%} of results for the 30 isolates tested fell within a mode one dilution range across all 17 laboratories. MIC2 at 24 h in RPMI 1640 or AM3 also gave the best interlaboratory separation of Candida isolates of known high and low susceptibility to caspofungin. Reproducibility of MIC data was problematic for caspofungin tests with Aspergillus spp. under all conditions, but the minimal effective concentration end point, defined as the lowest caspofungin concentration yielding conspicuously aberrant hyphal growth, gave excellent reproducibility for data from 14 of the 17 participating laboratories.",
    keywords = "IN-VITRO ACTIVITY, MK-0991 L-743,872, ANTIFUNGAL AGENTS, AMPHOTERICIN-B, ECHINOCANDIN, LY303366, RESISTANT, FUSARIUM, FUNGI, ETEST",
    author = "Odds, {Frank Christopher} and R. Andrade and J. Bille and E. Canton and M. Cuenca-Estrella and Davidson, {Amanda Denise} and C. Durussel and D. Ellis and E. Foraker and Fothergill, {A. W.} and Ghannoum, {M. A.} and Giacobbe, {R. A.} and M. Gobernado and R. Handke and M. Motyl",
    year = "2004",
    doi = "10.1128/JCM.42.8.3475-3482.2004",
    language = "English",
    volume = "42",
    pages = "3475--3482",
    journal = "Journal of Clinical Microbiology",
    issn = "0095-1137",
    publisher = "American Society for Microbiology",
    number = "8",

    }

    TY - JOUR

    T1 - Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus Species

    AU - Odds, Frank Christopher

    AU - Andrade, R.

    AU - Bille, J.

    AU - Canton, E.

    AU - Cuenca-Estrella, M.

    AU - Davidson, Amanda Denise

    AU - Durussel, C.

    AU - Ellis, D.

    AU - Foraker, E.

    AU - Fothergill, A. W.

    AU - Ghannoum, M. A.

    AU - Giacobbe, R. A.

    AU - Gobernado, M.

    AU - Handke, R.

    AU - Motyl, M.

    PY - 2004

    Y1 - 2004

    N2 - Seventeen laboratories participated in a study of interlaboratory reproducibility with caspofungin microdilution susceptibility testing against panels comprising 30 isolates of Candida spp. and 20 isolates of Aspergillus spp. The laboratories used materials supplied from a single source to determine the influence of growth medium (RPMI 1640 with or without glucose additions and antibiotic medium 3 [AM3]), the same incubation times (24 h and 48 h), and the same end point definition (partial or complete inhibition of growth) for the MIC of caspofungin. All tests were run in duplicate, and end points were determined both spectrophotometrically and visually. The results from almost all of the laboratories for quality control and reference Candida and Aspergillus isolates tested with fluconazole and itraconazole matched the NCCLS published values. However, considerable interlaboratory variability was seen in the results of the caspofungin tests. For Candida spp. the most consistent MIC data were generated with visual "prominent growth reduction" (MIC2) end points measured at 24 h in RPMI 1640, where 73.3% of results for the 30 isolates tested fell within a mode one dilution range across all 17 laboratories. MIC2 at 24 h in RPMI 1640 or AM3 also gave the best interlaboratory separation of Candida isolates of known high and low susceptibility to caspofungin. Reproducibility of MIC data was problematic for caspofungin tests with Aspergillus spp. under all conditions, but the minimal effective concentration end point, defined as the lowest caspofungin concentration yielding conspicuously aberrant hyphal growth, gave excellent reproducibility for data from 14 of the 17 participating laboratories.

    AB - Seventeen laboratories participated in a study of interlaboratory reproducibility with caspofungin microdilution susceptibility testing against panels comprising 30 isolates of Candida spp. and 20 isolates of Aspergillus spp. The laboratories used materials supplied from a single source to determine the influence of growth medium (RPMI 1640 with or without glucose additions and antibiotic medium 3 [AM3]), the same incubation times (24 h and 48 h), and the same end point definition (partial or complete inhibition of growth) for the MIC of caspofungin. All tests were run in duplicate, and end points were determined both spectrophotometrically and visually. The results from almost all of the laboratories for quality control and reference Candida and Aspergillus isolates tested with fluconazole and itraconazole matched the NCCLS published values. However, considerable interlaboratory variability was seen in the results of the caspofungin tests. For Candida spp. the most consistent MIC data were generated with visual "prominent growth reduction" (MIC2) end points measured at 24 h in RPMI 1640, where 73.3% of results for the 30 isolates tested fell within a mode one dilution range across all 17 laboratories. MIC2 at 24 h in RPMI 1640 or AM3 also gave the best interlaboratory separation of Candida isolates of known high and low susceptibility to caspofungin. Reproducibility of MIC data was problematic for caspofungin tests with Aspergillus spp. under all conditions, but the minimal effective concentration end point, defined as the lowest caspofungin concentration yielding conspicuously aberrant hyphal growth, gave excellent reproducibility for data from 14 of the 17 participating laboratories.

    KW - IN-VITRO ACTIVITY

    KW - MK-0991 L-743,872

    KW - ANTIFUNGAL AGENTS

    KW - AMPHOTERICIN-B

    KW - ECHINOCANDIN

    KW - LY303366

    KW - RESISTANT

    KW - FUSARIUM

    KW - FUNGI

    KW - ETEST

    U2 - 10.1128/JCM.42.8.3475-3482.2004

    DO - 10.1128/JCM.42.8.3475-3482.2004

    M3 - Article

    VL - 42

    SP - 3475

    EP - 3482

    JO - Journal of Clinical Microbiology

    JF - Journal of Clinical Microbiology

    SN - 0095-1137

    IS - 8

    ER -